Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults W... (us its Mono-Products(budesonide and form...)

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma

Date:9/10/2008

us its Mono-Products (budesonide and formoterol) in Adolescents (greater than or equal to 12 Years of Age) and Adults with Asthma. Drugs. 2006; 66(17):2235-2254. Accessed 05 August 2008. Available at: http://www.astrazenecaclinicaltrials.com.

(4) Corren, J., Korenblatt, P.E., Miller, C.J., O'Brien, C.D., Mezzanotte, W.S. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of SYMBICORT(R) pMDI (80/4.5 micrograms) versus its Monoproducts (budesonide and formoterol) in Children (greater than or equal to 6 Years of Age) and Adults with Asthma - SPRUCE 80/4.5. Clin Therapeutics. 2007; 29:823-843. Accessed 05 August 2008. Available at: http://www.astrazenecaclinicaltrials.com.

(5) What Are Lung Function Tests? National Heart, Lung and Blood Institute. Accessed 07 August 2008. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/lft/lft_all.html.

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

Post Your Comments:

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults W...(us its Mono-Products(budesonide and form...),Health